Debt AdvisoryHealthcareSIGNED
ViferaXS Secures €12 Million to Advance Oncology Pipeline and Clinical Trials
Value
€12M
Target
ViferaXS
ViferaXS has successfully closed a €12 million financing round, including grant funding, to advance its Phase II trial in chronic lymphocytic leukemia and expand its oncology pipeline. The round was led by SPRIND and Huma, with participation from private investors.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.